Previous 10 | Next 10 |
First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301). Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301. The combinati...
2023-10-03 08:51:33 ET More on PDS Biotech PDS Biotechnology (PDSB) Q2 2023 Earnings Call Transcript PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study The Prognosis For PDS Biotechnology PDS Biotech gains after updates on pivotal trial for...
Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint inhibitor (ICI) naïve; published 24-month survival rate of less than 30% for approved ICI 1 . Received feedback from US Food and Drug Administra...
Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally advanced cervical cancer in the IMMUNOCERV Phase 2 clinical trial and patients receiving standard of care (SOC) treatment Patients treated with PDS0101 had greater clearance of cfDNA as compared to those ...
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s prop...
Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunoth...
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s prop...
PDS0202 (Infectimune ® + COBRA influenza antigens) vaccination also prevented illness/weight loss Vaccine protected against replication of the virus in the lungs of ferrets after challenge with the H1N1 virus Data from Cleveland Clinic’s Ted Ross Lab presen...
PRINCETON, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s propriet...
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s prop...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NASDAQ Market:
PDS Biotechnology Corporation Website:
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...
Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15,...